The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 401–500 of 1,002
Hammond, S., Erridge, S., Mangal, N., Pacchetti, B., & Sodergren, M. H. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0048 · Cited by 46
Catalytic asymmetric synthesis of cannabinoids and menthol from neral
Grimm, J. A. A., Zhou, H., Properzi, R., Leutzsch, M., Bistoni, G., Nienhaus, J., & List, B. (2023) · Nature · doi:10.1038/s41586-023-05747-9 · Cited by 47
Medical cannabis: considerations for the anesthesiologist and pain physician
Beaulieu, P., Boulanger, A., Desroches, J., & Clark, A. J. (2016) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-016-0598-x · Cited by 49
THC and gabapentin interactions in a mouse neuropathic pain model
Atwal, N., Casey, S. L., Mitchell, V. A., & Vaughan, C. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.006 · Cited by 47
Sierra, S., Gupta, A., Gomes, I., Fowkes, M. E., Ram, A., Bobeck, E. N., & Devi, L. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00008 · Cited by 47
Hasin, D. S., Shmulewitz, D., Cerdá, M., Keyes, K. M., Olfson, M., Sarvet, A. L., & Wall, M. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030284 · Cited by 47
Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort
Osborne, A. J., Pearson, J. F., Noble, A. J., Gemmell, N. J., Horwood, L. J., Boden, J. M., Benton, M. C., Macartney-Coxson, D. P., & Kennedy, M. A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0800-3 · Cited by 47
Jacobs, N. I., Montebello, M. E., Monds, L. A., & Lintzeris, N. (2018) · Australasian Psychiatry · doi:10.1177/1039856218803675 · Cited by 46
Clearing the haze: the complexities and challenges of research on state marijuana laws
Choo, E. K., & Emery, S. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13093 · Cited by 46
Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews
Schussel, V. C., Kenzo, L., dos Santos, A. R. A., Bueno, J., Yoshimura, E., Latorraca, C. D. O. C., Pachito, D. V., & Riera, R. (2017) · Phytotherapy Research · doi:10.1002/ptr.5975 · Cited by 46
Schräder, N. H. B., Duipmans, J. C., Molenbuur, B., Wolff, A. P., & Jonkman, M. F. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17341 · Cited by 46
Efficacy of cannabinoids in paediatric epilepsy
Ali, S. S., Scheffer, I. E., & Sadleir, L. G. (2018) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14087 · Cited by 48
Cannabinoids: Potential Role in Inflammatory and Neoplastic Skin Diseases
Milando, R., & Friedman, A. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0410-5 · Cited by 50
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Williams, D. A., & Clauw, D. J. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.09.006 · Cited by 47
Current state of evidence of cannabis utilization for treatment of autism spectrum disorders
Agarwal, R., Burke, S. L., & Maddux, M. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2259-4 · Cited by 46
Medical cannabis in the UK: From principle to practice
Schlag, A. K., Baldwin, D. S., Barnes, M., Bazire, S., Coathup, R., Curran, H. V., McShane, R. H., Phillips, L. D., Singh, I., & Nutt, D. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120926677 · Cited by 49
Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience
Mostafavi, M., & Gaitanis, J. N. (2020) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2020.100833 · Cited by 56
Cannabinoids in Chronic Pain: Therapeutic Potential Through Microglia Modulation
van den Hoogen, N. J., Harding, E. K., Davidson, C. E. D., & Trang, T. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.816747 · Cited by 45
Asselin, A., Lamarre, O. B., Chamberland, R., McNeil, S.-J., Demers, E., & Zongo, A. (2022) · Journal of Cannabis Research · doi:10.1186/s42238-022-00135-y · Cited by 46
Differential regulation of Ca v 3.2 and Ca v 2.2 calcium channels by CB 1 receptors and cannabidiol
Harding, E. K., Souza, I. A., Gandini, M. A., Gadotti, V. M., Ali, M. Y., Huang, S., Antunes, F. T. T., Trang, T., & Zamponi, G. W. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16035 · Cited by 45
AAPM&R consensus guidance on spasticity assessment and management
Verduzco‐Gutierrez, M., Raghavan, P., Pruente, J. R., Moon, D., List, C. M., Hornyak, J. E., Gül, F., Deshpande, S., Biffl, S. E., Lawati, Z. A., et al. (2024) · PM&R · doi:10.1002/pmrj.13211 · Cited by 45
Self-citationIs there a role for cannabidiol in psychiatry?
Khoury, J. M., das Neves, M. D. C. L., Roque, M. A. V., Queiroz, D. A. D. B., de Freitas, A. A. C., de Fátima, Â., Moreira, F. A., & Garcia, F. D. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1285049 · Cited by 45
Pluskal, T., & Weng, J. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00411g · Cited by 46
Pearson, M. R. (2019) · Psychology of Addictive Behaviors · doi:10.1037/adb0000452 · Cited by 45
Rasera, G. B., Ohara, A., & de Castro, R. J. S. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.06.035 · Cited by 44
Barakji, J. A., Korang, S. K., Feinberg, J. B., Maagaard, M., Mathiesen, O., Gluud, C. N., & Jakobsen, J. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0267420 · Cited by 48
Biosynthesis of Phytocannabinoids and Structural Insights: A Review
Govindarajan, R. K., Mishra, A. K., Cho, K.-H., Kim, K.-H., Yoon, K. M., & Baek, K.-H. (2023) · Metabolites · doi:10.3390/metabo13030442 · Cited by 48
Cannabinoids: The Lows and the Highs of Chemotherapy-Induced Nausea and Vomiting
Mortimer, T. L., Mabin, T., & Engelbrecht, A. (2019) · Future Oncology · doi:10.2217/fon-2018-0530 · Cited by 43
Cannabis use in active athletes: Behaviors related to subjective effects
Zeiger, J. S., Silvers, W. S., Fleegler, E. M., & Zeiger, R. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218998 · Cited by 46
Medical cannabis for chronic pain: can it make a difference in pain management?
Maharajan, M. K., Yong, Y. J., Yip, H. Y., Woon, S. S., Yeap, K. M., Yap, K. Y., Yip, S. C., & Yap, K. X. (2019) · Journal of Anesthesia · doi:10.1007/s00540-019-02680-y · Cited by 46
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 44
Yu, L., Zeng, L., Zhang, Z., Zhu, G., Xu, Z., Xia, J., Weng, J., Jiang, L., & Pathak, J. L. (2023) · Biomolecules · doi:10.3390/biom13010118 · Cited by 43
Han, B. H., Brennan, J. J., Orozco, M. A., Moore, A. A., & Castillo, E. M. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18180 · Cited by 44
Cranford, J. A., Bohnert, K. M., Perron, B. E., Bourque, C. A., & Ilgen, M. A. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.008 · Cited by 43
Frequency of Cannabis Use Among Primary Care Patients in Washington State
Lapham, G. T., Lee, A. K., Caldeiro, R. M., McCarty, D. W., Browne, K. C., Walker, D. D., Kivlahan, D. R., & Bradley, K. A. (2017) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2017.06.170062 · Cited by 44
Delling, F. N., Vittinghoff, E., Dewland, T. A., Pletcher, M. J., Olgin, J. E., Nah, G., Aschbacher, K., Fang, C. D., Lee, E. S., Fan, S. M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027432 · Cited by 43
Moreau, M., Ibeh, U., Decosmo, K., Bih, N., Yasmin‐Karim, S., Toyang, N. J., Lowe, H. I. C., & Ngwa, W. F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00660 · Cited by 47
Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease
Gotfried, J., Naftali, T., & Schey, R. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.087 · Cited by 43
Use of Medical Cannabis to Treat Traumatic Brain Injury
Hergert, D. C., Robertson‐Benta, C. R., Sicard, V., Schwotzer, D., Hutchison, K. E., Covey, D. P., Quinn, D. K., Sadek, J. R., McDonald, J. D., & Mayer, A. R. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2020.7148 · Cited by 45
Development of an efficient yeast platform for cannabigerolic acid biosynthesis
Zhang, Y., Guo, J., Gao, P., Wei, Y., Shen, J., Luo, X., & Keasling, J. D. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2023.10.004 · Cited by 42
Luckett, T., Phillips, J. L., Lintzeris, N., Allsop, D., Lee, J. T., Solowij, N., Martin, J. H., Lam, L. T.-M., Aggarwal, R., McCaffrey, N., et al. (2016) · Internal Medicine Journal · doi:10.1111/imj.13224 · Cited by 42
Andrenyak, D. M., Moody, D. E., Slawson, M. H., OʼLeary, D. S., & Haney, M. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw136 · Cited by 42
Cannabis for restless legs syndrome: a report of six patients
Megelin, T., & Ghorayeb, I. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.04.019 · Cited by 42
Rovare, V. P. D. [., Magalhães, G. P. A., Jardini, G. D. A., Beraldo, M. L., Gameiro, M. O., Agarwal, A., Luvizutto, G. J., Ramos, L. D. P., Camargo, S. E. A., de Oliveira, L. D., et al. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.08.010 · Cited by 42
Hawley, L., Ketchum, J. M., Morey, C. E., Collins, K., & Charlifue, S. W. (2018) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2018.02.003 · Cited by 42
Shen, J. J., Shan, G., Kim, P. C., Yoo, J. W., Dodge‐Francis, C., & Lee, Y. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000479 · Cited by 42
Synthetic Cannabinoid Activity Against Colorectal Cancer Cells
Raup‐Konsavage, W. M., Johnson, M., Legare, C. A., Yochum, G. S., Morgan, D. J., & Vrana, K. E. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0065 · Cited by 42
Patterns of Marijuana Use and Health Impact: A Survey Among Older Coloradans
Lum, H. D., Arora, K., Croker, J. A., Qualls, S. H., Schuchman, M., Bobitt, J., Milavetz, G., & Kaskie, B. P. (2019) · Gerontology and Geriatric Medicine · doi:10.1177/2333721419843707 · Cited by 42
Evidence for the use of cannabinoids in Parkinson’s disease
Buhmann, C., Mainka, T., Ebersbach, G., & Gandor, F. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02018-8 · Cited by 42
Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 45
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Graczyk, M., Łukowicz, M., & Dzierżanowski, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.620073 · Cited by 45
Li, J., Carvajal, R., Bruner, L. H., & Kaminski, N. E. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112600 · Cited by 49
Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy
D'Souza, R. S., Alvarez, G. A. M., Dombovy‐Johnson, M. L., Eller, J. S., & Abd-Elsayed, A. A. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01107-4 · Cited by 86
Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder
Bollom, A., Austrie, J., Hirsch, W., Nee, J. W., Friedlander, D., Iturrino, J., Ballou, S., & Lembo, A. J. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000944 · Cited by 41
Cousijn, J., Núñez, A. E., & Filbey, F. M. (2017) · Addiction · doi:10.1111/add.14084 · Cited by 41
Misiołek, H., Zajączkowska, R., Daszkiewicz, A., Woroń, J., Dobrogowski, J., Wordliczek, J., & Owczuk, R. (2018) · Anaesthesiology Intensive Therapy · doi:10.5603/ait.2018.0026 · Cited by 43
Marijuana as a Substitute for Prescription Medications: A Qualitative Study
Mercurio, A. N., Aston, E. R., Claborn, K., Waye, K. M., & Rosen, R. K. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1618336 · Cited by 44
Naftali, T., Schleider, L. B., Benjaminov, F., Lish, I., Konikoff, F. M., & Ringel, Y. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001565 · Cited by 41
Perceived safety of cannabis intoxication predicts frequency of driving while intoxicated
Borodovsky, J. T., Marsch, L. A., Scherer, E. A., Grucza, R. A., Hasin, D. S., & Budney, A. J. (2019) · Preventive Medicine · doi:10.1016/j.ypmed.2019.105956 · Cited by 41
Gorfinkel, L., Stohl, M., Greenstein, E., Aharonovich, E., Olfson, M., & Hasin, D. S. (2020) · Addiction · doi:10.1111/add.15228 · Cited by 40
Harris, M., Erridge, S., Ergisi, M., Nimalan, D., Kawka, M., Salazar, O., Ali, R., Loupasaki, K., Holvey, C., Coomber, R., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2017771 · Cited by 42
Ang, S. P., Sidharthan, S., Lai, W. C., Hussain, N., Patel, K. V., Gulati, A., Henry, O., Kaye, A. D., & Orhurhu, V. (2023) · Pain and Therapy · doi:10.1007/s40122-022-00465-y · Cited by 43
Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study
Holt, A., Nouhravesh, N., Strange, J. E., Nielsen, S. K., Schjerning, A.-M., Rasmussen, P. V., Torp-Pedersen, C. T., Gislason, G., Schou, M., McGettigan, P., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad834 · Cited by 40
Cannabinoide in der palliativen Versorgung
Mücke, M., Carter, C., Cuhls, H., Prüß, M. S., Radbruch, L., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0085-2 · Cited by 40
Anesthetic implications of recreational drug use
Beaulieu, P. (2017) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-017-0975-0 · Cited by 40
Medical cannabis: A forward vision for the clinician
Fitzcharles, M., & Eisenberg, E. (2018) · European Journal of Pain · doi:10.1002/ejp.1185 · Cited by 39
Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
Chesney, E., McGuire, P. K., Freeman, T. P., Strang, J., & Englund, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954992 · Cited by 43
Vaughn, S., Strawn, J., Poweleit, E., Sarangdhar, M., & Ramsey, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070615 · Cited by 40
Medical marijuana: Showdown at the cannabis corral
Eisenstein, M. S. (2015) · Nature · doi:10.1038/525s15a · Cited by 39
Fischer, B., Kuganesan, S., Gallassi, A. D., Malcher‐Lopes, R., van den Brink, W., & Wood, E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.09.005 · Cited by 41
Is the medical use of cannabis a therapeutic option for children?
Rieder, M. J. (2016) · Paediatrics & Child Health · doi:10.1093/pch/21.1.31 · Cited by 39
Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD
Rein, J. L., & Wyatt, C. M. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.06.020 · Cited by 39
Cranford, J. A., Arnedt, J. T., Conroy, D. A., Bohnert, K. M., Bourque, C. A., Blow, F. C., & Ilgen, M. A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.08.017 · Cited by 39
Trends in Publications on Medical Cannabis from the Year 2000
Treister‐Goltzman, Y., Freud, T., Press, Y., & Peleg, R. (2018) · Population Health Management · doi:10.1089/pop.2018.0113 · Cited by 39
Maselli, D. B., & Camilleri, M. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.020 · Cited by 39
Aviram, J., Lewitus, G. M., Vysotski, Y., Uribayev, A., Procaccia, S., Cohen, I., Leibovici, A., Amna, M. A., Akria, L., Goncharov, D., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13120435 · Cited by 38
Meng, H., Pagé, M. G., Ajrawat, P., Deshpande, A., Samman, B., Dominicis, M., Ladha, K. S., Fiorellino, J., Huang, A., Kotteeswaran, Y., et al. (2021) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-020-01903-1 · Cited by 42
Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions
Brown, J. D., Rivera, K. J. R., Hernandez, L. Y. C., Doenges, M. R., Auchey, I., Pham, T., & Goodin, A. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1871 · Cited by 43
Khelemsky, Y., Goldberg, A. T., Hurd, Y. L., Winkel, G. H., Ninh, A., Qian, L. Y., Oprescu, A. M., Ciccone, J., & Katz, D. (2017) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000654 · Cited by 39
Cannabis, alcohol and cigarette use during the acute post-concussion period
Lawrence, D. W., Foster, E., Comper, P., Langer, L. K., Hutchison, M. G., Chandra, T., & Bayley, M. T. (2019) · Brain Injury · doi:10.1080/02699052.2019.1679885 · Cited by 38
Cannabis for the Treatment of Fibromyalgia: A Systematic Review
Strand, N. H., Maloney, J. A., Kraus, M. B., Wie, C. S., Turkiewicz, M., Gomez, D. A., Adeleye, O., & Harbell, M. W. (2023) · Biomedicines · doi:10.3390/biomedicines11061621 · Cited by 43
Tracking Dabbing Using Search Query Surveillance: A Case Study in the United States
Zhang, Z., Zheng, X., Zeng, D. D., & Leischow, S. J. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5802 · Cited by 38
Nugent, S. M., Yarborough, B. J. H., Smith, N. X., Dobscha, S. K., Deyo, R. A., Green, C. A., & Morasco, B. J. (2017) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2017.11.001 · Cited by 38
Cancer-Related Neuropathic Pain
Davis, M. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.01.005 · Cited by 37
Perceived support for medical cannabis use among approved medical cannabis users in Canada
Leos‐Toro, C., Shiplo, S., & Hammond, D. G. (2018) · Drug and Alcohol Review · doi:10.1111/dar.12823 · Cited by 38
Ragazzi, T. C. C., Shuhama, R., Menezes, P. R., & Del‐Ben, C. M. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12693 · Cited by 40
Pellesi, L., Licata, M., Verri, P., Vandelli, D., Palazzoli, F., Marchesi, F., Cainazzo, M. M., Pini, L. A., & Guérzoni, S. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2516-3 · Cited by 40
Orthopaedic surgery patients who use recreational marijuana have less pre-operative pain
Medina, S. H., Nadarajah, V., Jauregui, J. J., Smuda, M. P., Foster, M. J., Meredith, S. J., Packer, J. D., & Henn, R. F. (2018) · International Orthopaedics · doi:10.1007/s00264-018-4101-x · Cited by 38
Hawley, P. H., & Gobbo, M. (2019) · Current Oncology · doi:10.3747/co.26.4743 · Cited by 38
Efron, D., Freeman, J. L., Cranswick, N., Payne, J. M., Mulraney, M., Prakash, C., Lee, K. J., Taylor, K., & Williams, K. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14399 · Cited by 42
Hardy, J., Haywood, A., Gogna, G., Martin, J. H., Yates, P., Greer, R., & Good, P. (2020) · Trials · doi:10.1186/s13063-020-04541-6 · Cited by 33
Rock, E. M., Limebeer, C. L., Pertwee, R. G., Mechoulam, R., & Parker, L. A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0041 · Cited by 39
Kawka, M., Erridge, S., Holvey, C., Coomber, R., Usmani, A., Sajad, M., Platt, M. W., Rucker, J., & Sodergren, M. H. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1961 · Cited by 40
Ergisi, M., Erridge, S., Harris, M., Kawka, M., Nimalan, D., Salazar, O., Loupasaki, K., Ali, R., Holvey, C., Coomber, R., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2020640 · Cited by 40
Teleszko, M., Zając, A., & Rusak, T. (2022) · Molecules · doi:10.3390/molecules27041448 · Cited by 40
Addictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37
Suhre, W. M., O’Reilly-Shah, V. N., & Cleve, W. V. (2020) · BMC Anesthesiology · doi:10.1186/s12871-020-01036-4 · Cited by 37
Diagnosis and Acute Management of Adolescent Cannabinoid Hyperemesis Syndrome: A Systematic Review
Zhu, J. W., Gonsalves, C. L., Issenman, R. M., & Kam, A. J. (2020) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2020.07.035 · Cited by 37
Mechanisms of cannabinoid tolerance
Piscura, M. K., Henderson, A. N., Barnes, R. C., Mitra, S., Guindon, J., & Morgan, D. J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115665 · Cited by 40
Youssef, N. A., Schneider, M. P., Mordasini, L., Ineichen, B. V., Bachmann, L. M., Chartier-Kastler, E. J., Panicker, J. N., & Kessler, T. M. (2017) · British Journal of Urology · doi:10.1111/bju.13759 · Cited by 37
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
